|
|
|
|
|
|
Rheumatoid Arthritis – Clinical Development: Working with the product planning and
clinical development groups of a large pharmaceutical company, Health Advances identified and
interviewed key opinion leaders in rheumatoid arthritis to advise the company on the
prospects and clinical trial design of a new molecule in preclinical development and assembled
a panel of thought leaders for a six-hour focus group held with representatives from the company.
As a result of the project, the company significantly revised its clinical development program
to generate more substantial preclinical data prior to proceeding into the clinic.
Rheumatoid Arthritis – Product Strategy:
On behalf of a large biotechnology company, Health Advances designed a conjoint study and survey
to assess rheumatologists’ anticipated use of novel treatments for rheumatoid arthritis. The study
assessed rheumatologist trade-offs between multiple new therapies expected to enter the market
in the near future, including new biologics, follow-on biologics, and novel small molecule
treatments.
Multiple Sclerosis – Franchise Strategy:
Health Advances completed a franchise strategy optimization for a company’s neuro-immunology
division. Health Advances worked with senior management to define the vision, strategy, goals,
and metrics for the franchise moving forward. As part of this process, Health Advances investigated
and prioritized activities within five key strategic initiatives and proposed recommendations
along with short and mid-term action plans.
Multiple Sclerosis– Biosimilar Commercialization:
Health Advances worked with an emerging biosimilar manufacturer to develop a commercialization
strategy for a biosimilar interferon-beta in the US and EU. Health Advances conducted interviews
with physicians, payers, pharmacists, wholesalers, regulatory experts, and industry experts to
understand the spectrum of issues that will accompany a new biosimilar launch. In particular,
we sought to understand the relevant stakeholders in each country and how best to engage with
each to ensure success. The end result was the identification and prioritization of market-specific
success factors and action steps for our client to use when developing the launch plan for their
product.
Psoriasis – Formulation:
On behalf of a biotech company, Health Advances assessed the potential impact of delivery format
on the roll-out and acceptance of an infused drug for psoriasis. In addition to the US market,
hurdles and opportunities relating to the logistics of the product’s potential use in France and
Germany were also identified. A detailed understanding of the approval and adoption practices
within these countries was crucial to outlining the how the client could maximize adoption of
its product in a market that historically had few or no infusion-based therapies.
Crohn’s Disease – Forecasting:
Health Advances created a patient flow forecast model of Crohn’s disease in the US, 5EU, and
Japan to support a large pharmaceutical company’s clinical development program. Model assumptions
were based on market research reports, interviews with gastroenterologist and rheumatologist KOLs,
and a detailed analysis of clinical literature, pipeline compounds, and clinical trials. A “lines
of therapy” framework was used to define a patient transition matrix with numerous positions for
a new therapy to penetrate to allow for a flexible, scenario-based model.
Systemic Lupus Erythematosus – International Market Assessment:
Health Advances worked a large pharmaceutical company to conduct a comprehensive evaluation of
the market for systemic lupus erythematosus (SLE) and lupus nephritis therapies in the US, EU,
Japan and China. Working with the company we developed a perspective on the opportunity and
potential fit for SLE in the broader strategy. Over 75 interviews were conducted in the US, EU,
Japan and China with both thought leaders and practicing rheumatologists. “Patient flow”
interviews reviewing specific patient charts were utilized to accurately capture real treatment
practice. A detailed forecast model was developed and future therapies and clinical development
challenges were evaluated in depth.
|
|
 |
|
|
|
|
